Literature DB >> 21940196

Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Anthony Griffiths1.   

Abstract

Some of the most successful antiviral agents currently available are effective against herpes simplex virus. However, resistance to these drugs is frequently associated with significant morbidity, particularly in immunocompromised patients. In addition to the clinical implications of drug resistance, the range of biological processes exploited by the virus to attain resistance while maintaining pathogenicity is proving to be surprising. These mechanisms, which include ribosomal frameshifting, induced infidelity of the DNA polymerase, and internal ribosome entry, are discussed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940196      PMCID: PMC3195865          DOI: 10.1016/j.drup.2011.08.003

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  66 in total

1.  The role of herpes simplex virus type 1 thymidine kinase in pathogenesis.

Authors:  S Efstathiou; S Kemp; G Darby; A C Minson
Journal:  J Gen Virol       Date:  1989-04       Impact factor: 3.891

2.  Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1.

Authors:  R B Tenser; K A Hay; W A Edris
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Latent infections in spinal ganglia with thymidine kinase-deficient herpes simplex virus.

Authors:  T P Leist; R M Sandri-Goldin; J G Stevens
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir.

Authors:  J C Wade; C McLaren; J D Meyers
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

5.  Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.

Authors:  M N Ellis; R Waters; E L Hill; D C Lobe; D W Selleseth; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

6.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

Authors:  D M Coen; M Kosz-Vnenchak; J G Jacobson; D A Leib; C L Bogard; P A Schaffer; K L Tyler; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

Authors:  S L Sacks; R J Wanklin; D E Reece; K A Hicks; K L Tyler; D M Coen
Journal:  Ann Intern Med       Date:  1989-12-01       Impact factor: 25.391

8.  Phosphorylation of acyclovir diphosphate by cellular enzymes.

Authors:  W H Miller; R L Miller
Journal:  Biochem Pharmacol       Date:  1982-12-01       Impact factor: 5.858

9.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.

Authors:  D S Parris; J E Harrington
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA.

Authors:  J Pelletier; N Sonenberg
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

View more
  11 in total

1.  Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells.

Authors:  Dongli Pan; Donald M Coen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Identification and characterization of a -1 reading frameshift in the heavy chain constant region of an IgG1 recombinant monoclonal antibody produced in CHO cells.

Authors:  Zhirui Lian; Qindong Wu; Tongtong Wang
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

Review 3.  Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use.

Authors:  John F Atkins; Gary Loughran; Pramod R Bhatt; Andrew E Firth; Pavel V Baranov
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

4.  Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection.

Authors:  Mandy Glass; Roger D Everett
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

5.  Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient.

Authors:  Dongli Pan; Stephen B Kaye; Mark Hopkins; Ruaidhri Kirwan; Ian J Hart; Donald M Coen
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

Review 6.  Antiviral drug resistance as an adaptive process.

Authors:  Kristen K Irwin; Nicholas Renzette; Timothy F Kowalik; Jeffrey D Jensen
Journal:  Virus Evol       Date:  2016-06-10

7.  Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance.

Authors:  Natalia Korniy; Akanksha Goyal; Markus Hoffmann; Ekaterina Samatova; Frank Peske; Stefan Pöhlmann; Marina V Rodnina
Journal:  Nucleic Acids Res       Date:  2019-06-04       Impact factor: 16.971

Review 8.  Mechanisms and biomedical implications of -1 programmed ribosome frameshifting on viral and bacterial mRNAs.

Authors:  Natalia Korniy; Ekaterina Samatova; Maria M Anokhina; Frank Peske; Marina V Rodnina
Journal:  FEBS Lett       Date:  2019-06-20       Impact factor: 4.124

Review 9.  Alphaherpesvirus Genomics: Past, Present and Future.

Authors:  Chad V Kuny; Moriah L Szpara
Journal:  Curr Issues Mol Biol       Date:  2020-11-07       Impact factor: 2.081

10.  Ribosomal frameshifting used in influenza A virus expression occurs within the sequence UCC_UUU_CGU and is in the +1 direction.

Authors:  A E Firth; B W Jagger; H M Wise; C C Nelson; K Parsawar; N M Wills; S Napthine; J K Taubenberger; P Digard; J F Atkins
Journal:  Open Biol       Date:  2012-10       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.